AcuCort

After consultation with the company’s largest shareholders in terms of votes, as of September 30, 2024, the nomination committee consists of the following members, with Jan Poulsen newly appointed as a member of the nomination committee:

•    Gustaf Albèrt, Aqilion AB, chair of the nomination committe.
•    Thomas Nestenius, appointed by Zoya Invest AB
•    Jan Poulsen, appointed by Life Science Investment Fund (LSIF)

The Annual General Meeting will be held May 12th 2024 in Lund. The Nomination Committee’s proposals will be presented in the notice of the Annual General Meeting and on the company’s website. 

For further information: 
Ebba Fåhreus, styrelsens ordförande 
Telefon: 073 400 04 33
Epost: ebba@smileincubator.life

About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.